[Granulocyte colony-stimulating factor: biologic effects and possibilities of therapeutic use].
This review is a brief overview on recent advances in biology as well as in the potential clinical application of recombinant methionil human granulocyte colony-stimulating factor (r-metHuG-CSF). Biologically active human granulocyte colony-stimulating factor is a recombinant human protein expressed in Escherichia coli. It is localized on membrane of stroma cells in molecules of extracellular matrix. R-metHuG-CSF increases the number of circulating neutrophils, and to a much lesser extent macrophages. The clinically relevant uses of r-metHuG-CSF at present lie in two general areas: neutropenia and febrile netropenia present in patients with non-myeloid malignant diseases induced by anticancer agents. R-metHuG-CSF produces dose-dependent and reversible side effects such as: musculoskeletal pain, urinary disorders, retention of fluid, pericarditis, dyspnea, hypoxia and hypotension.